Anti-inflammatory agent 86
Anti-inflammatory agent 86 is a Chrysin (HY-14589) derivative with anti-inflammatory effects. Anti-inflammatory agent 86 inhibits monocyte adhesion to colon epithelium induced by TNF-α, with an IC50 of 4.71 μM. Anti-inflammatory agent 86 has the potential for the inflammatory bowel disease (IBD) research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C29H34N2O5S2
- Molecular Weight:554.72
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
In Vitro
Anti-inflammatory agent 86 (compound 4b) exhibits significant inhibitory activity against the adhesion of monocytes to HT-29 cells induced by TNF-α, with an IC50 value of 4.71 μM[1].
Anti-inflammatory agent 86 (5-10 μM; 4 h) significantly suppresses the expression of MCP-1 in a concentration-dependent manner. Anti-inflammatory agent 86 inhibits NF-κB activity in HT-29 cells in a dose-dependent manner[1].
Anti-inflammatory agent 86 (5-10 μM) demonstrates a notable inhibitory effect on the generation of ROS induced by TNF-α in a dose-dependent fashion[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:TNF-α-stimulated HT-29 cells
-
Concentration:5 μM, 10 μM
-
Incubation Time:Pretreatment with 1 h and then treat for 3 hours
-
Result:Effectively suppressed TNF-α-induced intercellular adhesion molecule (ICAM)-1 expression in a manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Sprague-Dawley (SD) rats bearing colitis (induced by 2, 4, 6-trinitrobenzenesulfonic acid (TNBS))[1].
-
Dosage:30 mg/kg/day or 60 mg/kg/day (10% DMSO, 15% SBE-β-CD, and 75% saline)
-
Administration:po; once daily; for 15 days
-
Result:Exhibiteds a dose-dependent inhibition of 2, 4, 6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in rats.
Chemical Information
-
Molecular Weight 554.72
-
Formel C29H34N2O5S2
-
SMILES
O=C(N1CCN(CCOC2=CC(OC(C3=CC=CC=C3)=CC4=O)=C4C(O)=C2)CC1)CCCCC5CCSS5
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)